Physician profile
Thomas Michael Townsend
NPI 1053382812
$284.76
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $26.98 · 2021: $34.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $127.54 | 2019 | |
| Lemaitre Vascular, INC. | $45.15 | 2019 | |
| Olympus America INC. | $34.93 | 2019-2021 | |
| Stryker Corporation | $20.00 | 2019 | |
| Heron Therapeutics, INC. | $16.34 | 2021 | |
| Kci USA, INC. | $15.79 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $13.82 | 2019 | |
| Covidien LP | $11.19 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.